Earnings History Data for Altimmune, Inc. (ALT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Altimmune, Inc.

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	PM		ALT	Altimmune, Inc.	545.82	-0.32	-0.35	-0.39	Altimmune beats Q3 estimates [11/12/2024 7:05 AM]	9.46	2.11 (28.64%)	7.53	0.18 (2.45%)	2.32 - 14.84	17,719,874	2,710,000	248,009
Altimmune Q3 2024 Earnings Preview [11/11/2024 1:12 PM] Altimmune names Greg Weaver as CFO [11/11/2024 7:54 AM] Altimmune beats Q3 estimates [11/12/2024 7:05 AM] Altimmune stock rallies 30% on business updates, UBS buy rating [11/12/2024 2:17 PM] Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update [2024-11-12 07:00AM] Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer [Nov-11-24 07:30AM] Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Nov-11-24 07:30AM]
08-08-2024	PM		ALT	Altimmune, Inc.	419.39	-0.35	-0.34	-0.32	Altimmune GAAP EPS of -$0.35 misses by $0.01 [8/8/2024 7:08 AM]	6.29	0.79 (14.45%)	5.80	0.30 (5.45%)	2.09 - 14.84	5,232,011	2,340,000	54,563
Altimmune Q2 2024 Earnings Preview [8/7/2024 1:49 PM] Altimmune GAAP EPS of -$0.35 misses by $0.01 [8/8/2024 7:08 AM]
09-05-2024	PM		ALT	Altimmune, Inc.	515.41	-0.34	-0.36	-0.40	Altimmune GAAP EPS of -$0.34 beats by $0.02 [5/9/2024 7:05 AM]	7.71	0.55 (7.75%)	7.15	-0.01 (-0.14%)	2.09 - 14.84	3,760,808	2,930,000	82,157
Altimmune GAAP EPS of -$0.34 beats by $0.02 [5/9/2024 7:05 AM] Altimmune Q1 2024 Earnings Preview [5/8/2024 2:12 PM]
27-03-2024	PM		ALT	Altimmune, Inc.	458.31	-0.33	-0.34	-0.43	Altimmune GAAP EPS of -$0.54 misses by $0.16 [3/27/2024 7:02 AM]	8.89	0.24 (2.77%)	9.30	0.65 (7.51%)	2.09 - 14.84	7,624,022	4,140,000	2,827,931
Altimmune falls after Q4 results; obesity drug data released [3/27/2024 8:26 AM] Altimmune GAAP EPS of -$0.54 misses by $0.16 [3/27/2024 7:02 AM] Altimmune Q4 2023 Earnings Preview [3/26/2024 1:52 PM]
07-11-2023	PM		ALT	Altimmune, Inc.	144.36	-0.39	-0.40	-0.48	Altimmune GAAP EPS of -$0.39 beats by $0.03, revenue of $0.36M beats by $0.36M [11/7/2023 7:04 AM]	2.71	0.04 (1.50%)	2.76	0.09 (3.37%)	2.09 - 17.17	1,536,706	1,590,000	19,634
Altimmune Q3 2023 Earnings Preview [11/6/2023 12:21 PM] Altimmune GAAP EPS of -$0.39 beats by $0.03, revenue of $0.36M beats by $0.36M [11/7/2023 7:04 AM]
10-08-2023	PM		ALT	Altimmune, Inc.	148.37	-0.32	-0.44	-0.42	Altimmune GAAP EPS of -$0.32 beats by $0.13 [8/10/2023 7:01 AM]	3.04	0.09 (3.05%)	3.02	0.07 (2.44%)	2.89 - 23.49	2,076,417	1,250,000	28,645
Altimmune Q2 2023 Earnings Preview [8/9/2023 12:07 PM] Altimmune GAAP EPS of -$0.32 beats by $0.13 [8/10/2023 7:01 AM]
11-05-2023	PM	7:00 AM ET (May 11)	ALT	Altimmune, Inc.	243.44	-0.40	-0.49	-0.44	Altimmune GAAP EPS of -$0.40 beats by $0.08 [5/11/2023 7:01 AM]	5.33	0.35 (7.13%)	5.01	0.03 (0.60%)	3.82 - 23.49	1,484,217	1,140,000	7,031
Altimmune GAAP EPS of -$0.40 beats by $0.08 [5/11/2023 7:01 AM]
28-02-2023	PM	7:00 AM ET (Feb 28)	ALT	Altimmune, Inc.	573.69	-0.43	-0.52	-0.49	Altimmune GAAP EPS of -$0.43 beats by $0.11 [2/28/2023 7:03 AM]	12.57	0.74 (6.26%)	11.91	0.08 (0.68%)	3.83 - 23.49	705,718	950,000	1,729
Altimmune Q4 2022 Earnings Preview [2/27/2023 6:00 PM] Altimmune GAAP EPS of -$0.43 beats by $0.11 [2/28/2023 7:03 AM]
10-11-2022	PM	7:00 AM ET (Nov 10)	ALT	Altimmune, Inc.	509.37	-0.48	-0.49	-0.81	Altimmune GAAP EPS of -$0.48 beats by $0.01 [11/10/2022 7:02 AM]	10.55	0.86 (8.88%)	10.07	0.38 (3.92%)	3.83 - 23.49	1,343,351	1,260,000	810
Altimmune GAAP EPS of -$0.48 beats by $0.01 [11/10/2022 7:02 AM] Altimmune rises 5.2% on smaller-than-expected Q3 loss [11/10/2022 11:10 AM] Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update [Nov-10-22 07:00AM]
11-08-2022	PM	7:00 AM ET (Aug 11)	ALT	Altimmune, Inc.	565.31	-0.42	-0.45	-0.40	Altimmune GAAP EPS of -$0.42 beats by $0.05, revenue of $8K [8/11/2022 7:03 AM]	13.75	0.89 (6.92%)	12.91	0.05 (0.39%)	3.83 - 17.26	1,162,278	1,390,000	28,213
Altimmune Q2 2022 Earnings Preview [8/10/2022 1:26 PM] Altimmune GAAP EPS of -$0.42 beats by $0.05, revenue of $8K [8/11/2022 7:03 AM] Altimmune quarterly net loss narrows as it beats on the bottom line [8/11/2022 9:38 AM]
12-05-2022	PM	7:00 AM ET (May 12)	ALT	Altimmune, Inc.	184.56	-0.44	-0.57	-0.38	Altimmune GAAP EPS of -$0.44 beats by $0.14, revenue of $0.03M misses by $0.85M [5/12/2022 7:02 AM]	4.29	0.35 (8.76%)	3.95	0.01 (0.25%)	3.83 - 19.46	768,620	740,000	236
Altimmune Q1 2022 Earnings Preview [5/11/2022 1:19 PM] Altimmune GAAP EPS of -$0.44 beats by $0.14, revenue of $0.03M misses by $0.85M [5/12/2022 7:02 AM] Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update [May-12-22 07:00AM]
15-03-2022	PM	4:00 PM ET (Mar 14)	ALT	Altimmune	297.00	-0.49	-0.64	0.00	Altimmune GAAP EPS of -$0.57 beats by $0.08, revenue of $3.28M beats by $3.19M [3/15/2022 7:42 AM]	5.86	-0.57 (-8.94%)	6.60	0.17 (2.64%)	5.78 - 19.46	1,140,393	745,076	29,489
Altimmune GAAP EPS of -$0.57 beats by $0.08, revenue of $3.28M beats by $3.19M [3/15/2022 7:42 AM] Altimmune stock falls ~5% despite Q4 beat [3/15/2022 10:34 AM] Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update [Mar-15-22 07:01AM]
17-05-2021	PM	7:00 AM ET (May 17)	ALT	Altimmune, Inc.	492.99	-0.38	-0.39	-0.26	Altimmune EPS beats by $0.28, misses on revenue [5/17/2021 7:05 AM]	14.18	0.80 (5.98%)	13.15	-0.23 (-1.72%)	4.36 - 35.10	890,393	770,000	3,848
Altimmune EPS beats by $0.28, misses on revenue [5/17/2021 7:05 AM] Altimmune Q1 loss soars 282% as expenses rise dramatically; shares up ~3% [5/17/2021 11:54 AM] Altimmune, Inc. to Host Earnings Call [May-17-21 06:45AM] Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update [May-17-21 07:00AM]
25-02-2021	PM	Before the open (Feb 25)	ALT	Altimmune, Inc.	851.69	-0.17	-0.84	-0.25	Altimmune EPS beats by $0.68, beats on revenue [2/25/2021 7:19 AM]	17.15	-2.43 (-12.41%)	19.00	-0.58 (-2.96%)	1.60 - 35.10	2,268,333	1,703,678	29,058
Altimmune EPS beats by $0.68, beats on revenue [2/25/2021 7:19 AM] Altimmune starts enrollment in phase 1 COVID-19 trial of Adcovid [2/25/2021 7:10 AM] Altimmune shares down 8% despite 2020 earnings, revenue beat [2/25/2021 12:04 PM] Positive news on COVID vaccines weighs against concerns over new variants [Feb-25-21 11:26AM] Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate [Feb-25-21 10:42AM]
09-11-2020	AH	7:15 AM ET (Nov 10)	ALT	Altimmune, Inc.	408.11	-0.54	-0.92	-0.18	Altimmune EPS beats by $0.22, beats on revenue [11/9/2020 4:45 PM]	9.34	0.90 (19.14%)	8.80	0.96 (12.32%)	1.51 - 35.10	4,148,621	1,287,661	132,786

11-08-2020	AH	7:15 AM ET (Aug 12)	ALT	Altimmune, Inc.	835.10	-0.94	-0.29	-0.26	Altimmune EPS misses by $0.66, misses on revenue [8/11/2020 4:26 PM]	23.70	0.60 (2.58%)	22.57	-0.53 (-2.29%)	1.51 - 35.10	1,488,112	1,950,339	19,149

13-05-2020	AH	7:15 AM ET (May 14)	ALT	Altimmune, Inc.	56.84	-0.26	-0.32	-0.27	Altimmune EPS beats by $0.06, beats on revenue [5/13/2020 5:27 PM]	4.49	0.36 (8.72%)	4.62	0.13 (2.90%)	1.51 - 5.74	20,194,490	1,249,407	78,162